Eltrombopag Use in Children with Persistent and Chronic Primary Immune Thrombocytopenia in a Portuguese Pediatric Center

Caroline Lopes; Ana Castro; Raquel Maia; Sara Batalha; Paula Kjöllerström

doi:10.20344/amp.20532

Eltrombopag Use in Children with Persistent and Chronic Primary Immune Thrombocytopenia in a Portuguese Pediatric Center

Authors

Caroline Lopes Department of Pediatrics. Hospital Dona Estefânia. Lisbon.
Ana Castro Hematology Unit. Hospital Dona Estefânia. Lisbon.
Raquel Maia Hematology Unit. Hospital Dona Estefânia. Lisbon.
Sara Batalha Hematology Unit. Hospital Dona Estefânia. Lisbon.
Paula Kjöllerström Hematology Unit. Hospital Dona Estefânia. Lisbon.

DOI:

https://doi.org/10.20344/amp.20532

Keywords:

Child, Purpura, Thrombocytopenic, Idiopathic/drug therapy, Receptors, Thrombopoietin, Thrombocytopenia/drug therapy

Abstract

N/a.

Downloads

Download data is not yet available.

References

Chen M, Fang JP, Zhou CX, Li XY, Lin SF, Xu LH. Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia. Hematology. 2021;26:31-6. DOI: https://doi.org/10.1080/16078454.2020.1856511

Giordano P, Lassandro G, Barone A, Cesaro S, Fotzi I, Giona F, et al. Use of eltrombopag in children with chronic immune thrombocytopenia (ITP): a real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Front Med. 2020;7:66. DOI: https://doi.org/10.3389/fmed.2020.00066

Cheng X, Fu LL, Ma J, Gu H, Chen Z, Zhao L, et al. Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice. Blood Adv. 2021;5:3799-806. DOI: https://doi.org/10.1182/bloodadvances.2020004110

Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386:1649-58. DOI: https://doi.org/10.1016/S0140-6736(15)61107-2

Palumbo G, Farruggia P, Ramenghi U, Russo G, Borchiellini A, Spinelli M, et al. Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy. Hematology. 2023;28:2210906. DOI: https://doi.org/10.1080/16078454.2023.2210906

Downloads

Published

2024-04-01

How to Cite

Lopes C, Castro A, Maia R, Batalha S, Kjöllerström P. Eltrombopag Use in Children with Persistent and Chronic Primary Immune Thrombocytopenia in a Portuguese Pediatric Center. Acta Med Port [Internet]. 2024 Apr. 1 [cited 2026 Jul. 26];37(4):294-5. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/20532

Download Citation

Issue

Vol. 37 No. 4 (2024): April

Section

Letters to the Editor

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.